서브메뉴
검색
Improving Access to Alcohol Use Disorder Pharmacotherapy in Hepatology: A Quality Improvement Initiative
Improving Access to Alcohol Use Disorder Pharmacotherapy in Hepatology: A Quality Improvement Initiative
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202103704
- ISBN
- 9798280722279
- DDC
- 610.73
- 서명/저자
- Improving Access to Alcohol Use Disorder Pharmacotherapy in Hepatology: A Quality Improvement Initiative
- 발행사항
- [Sl] : University of California, Los Angeles, 2025
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2025
- 형태사항
- 60 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
- 주기사항
- Advisor: Robbins, Wendie A.
- 학위논문주기
- Thesis (D.N.P.)--University of California, Los Angeles, 2025.
- 초록/해제
- 요약Background: Alcohol-associated liver disease (ALD) is the leading cause of liver-related morbidity and mortality in North America. Despite strong evidence supporting pharmacologic treatment for alcohol use disorder (AUD), pharmacotherapy remains significantly underutilized in hepatology settings. Identified barriers include provider unfamiliarity, safety concerns in cirrhosis, and system-level workflow limitations. Aim: To increase prescription rates of AUD pharmacotherapy in a high-volume hepatology clinic through targeted, scalable quality improvement interventions integrated into existing workflows. Methods: This single-center, quasi-experimental quality improvement study compared two cohorts of adults with ALD and active alcohol use seen in a hepatology clinic: pre-intervention (January-March 2023; n=143) and post-intervention (January-March 2025; n=175). Interventions included provider education, standardized alcohol screening, integration of decision-support tools (including a prescribing algorithm and documentation templates), and improved access to long-acting injectable medication. Outcomes were assessed via retrospective chart review. Multivariable logistic regression using backward stepwise elimination was performed to identify predictors of alcohol use disorder pharmacotherapy initiation. Results: AUD pharmacotherapy prescribing increased significantly from 10% pre-intervention to 43% post-intervention (p0.00001). Documented discussions of pharmacotherapy rose from 33% to 80% (p0.00001), while deferral to psychiatry or primary care decreased from 7% to 1% (p=0.006), indicating enhanced provider engagement and prescribing autonomy. Among those prescribed treatment, use of first-line agents such as oral naltrexone and acamprosate increased, and long-acting medication (Vivitrol) was newly adopted. Regression analysis (AUC=0.77) identified three independent predictors of pharmacotherapy initiation: post-intervention year (OR=6.03, 95% CI [3.20-11.34], p0.001), recent positive phosphatidylethanol (PEth) test (OR=2.44 vs. no PEth, 95% CI [1.28-4.64], p=0.007), and a trend toward lower Child-Turcotte Pugh (CTP) scores (OR=0.87, 95% CI [0.75-1.00], p=0.057). Model deviance R² was 16.2%, reflecting moderate fit likely influenced by unmeasured variables such as patient readiness for behavioral change. Conclusion: Embedded, interdisciplinary quality improvement interventions can substantially increase alcohol use disorder pharmacotherapy rates in hepatology without requiring structural clinic overhauls. This approach enhanced provider autonomy, reduced unnecessary deferrals, and optimized the use of clinical tools such as PEth testing. Findings support broader implementation of pragmatic, evidence-based strategies to improve alcohol use disorder care for patients with alcohol-associated liver disease in specialty settings.
- 일반주제명
- Nursing
- 일반주제명
- Pharmacology
- 일반주제명
- Medicine
- 일반주제명
- Clinical psychology
- 키워드
- Nurse-led
- 키워드
- Pharmacotherapy
- 기타저자
- University of California, Los Angeles Nursing 0597
- 기본자료저록
- Dissertations Abstracts International. 86-12B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2025 us c eng d■001000017358242
■00520260202103704
■006m o d
■007cr#unu||||||||
■020 ▼a9798280722279
■035 ▼a(MiAaPQ)AAI32113345
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a610.73
■1001 ▼aCollier, Summer Brianne.
■24510▼aImproving Access to Alcohol Use Disorder Pharmacotherapy in Hepatology: A Quality Improvement Initiative
■260 ▼a[Sl]▼bUniversity of California, Los Angeles▼c2025
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2025
■300 ▼a60 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 86-12, Section: B.
■500 ▼aAdvisor: Robbins, Wendie A.
■5021 ▼aThesis (D.N.P.)--University of California, Los Angeles, 2025.
■520 ▼aBackground: Alcohol-associated liver disease (ALD) is the leading cause of liver-related morbidity and mortality in North America. Despite strong evidence supporting pharmacologic treatment for alcohol use disorder (AUD), pharmacotherapy remains significantly underutilized in hepatology settings. Identified barriers include provider unfamiliarity, safety concerns in cirrhosis, and system-level workflow limitations. Aim: To increase prescription rates of AUD pharmacotherapy in a high-volume hepatology clinic through targeted, scalable quality improvement interventions integrated into existing workflows. Methods: This single-center, quasi-experimental quality improvement study compared two cohorts of adults with ALD and active alcohol use seen in a hepatology clinic: pre-intervention (January-March 2023; n=143) and post-intervention (January-March 2025; n=175). Interventions included provider education, standardized alcohol screening, integration of decision-support tools (including a prescribing algorithm and documentation templates), and improved access to long-acting injectable medication. Outcomes were assessed via retrospective chart review. Multivariable logistic regression using backward stepwise elimination was performed to identify predictors of alcohol use disorder pharmacotherapy initiation. Results: AUD pharmacotherapy prescribing increased significantly from 10% pre-intervention to 43% post-intervention (p0.00001). Documented discussions of pharmacotherapy rose from 33% to 80% (p0.00001), while deferral to psychiatry or primary care decreased from 7% to 1% (p=0.006), indicating enhanced provider engagement and prescribing autonomy. Among those prescribed treatment, use of first-line agents such as oral naltrexone and acamprosate increased, and long-acting medication (Vivitrol) was newly adopted. Regression analysis (AUC=0.77) identified three independent predictors of pharmacotherapy initiation: post-intervention year (OR=6.03, 95% CI [3.20-11.34], p0.001), recent positive phosphatidylethanol (PEth) test (OR=2.44 vs. no PEth, 95% CI [1.28-4.64], p=0.007), and a trend toward lower Child-Turcotte Pugh (CTP) scores (OR=0.87, 95% CI [0.75-1.00], p=0.057). Model deviance R² was 16.2%, reflecting moderate fit likely influenced by unmeasured variables such as patient readiness for behavioral change. Conclusion: Embedded, interdisciplinary quality improvement interventions can substantially increase alcohol use disorder pharmacotherapy rates in hepatology without requiring structural clinic overhauls. This approach enhanced provider autonomy, reduced unnecessary deferrals, and optimized the use of clinical tools such as PEth testing. Findings support broader implementation of pragmatic, evidence-based strategies to improve alcohol use disorder care for patients with alcohol-associated liver disease in specialty settings.
■590 ▼aSchool code: 0031.
■650 4▼aNursing
■650 4▼aPharmacology
■650 4▼aMedicine
■650 4▼aClinical psychology
■653 ▼aAlcohol associated liver disease
■653 ▼aAlcohol use disorder
■653 ▼aNurse practitioners
■653 ▼aNurse-led
■653 ▼aPharmacotherapy
■653 ▼aQuality improvement
■690 ▼a0569
■690 ▼a0564
■690 ▼a0622
■690 ▼a0419
■71020▼aUniversity of California, Los Angeles▼bNursing 0597.
■7730 ▼tDissertations Abstracts International▼g86-12B.
■790 ▼a0031
■791 ▼aD.N.P.
■792 ▼a2025
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17358242▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.


